GlassScriptPhysician profile
Luis Baez Vallecillo
NPI 1265788855
$106,588.68
in general payments reported to CMS, 2019-2025
49 companies · $9,086 in 2025
The $9,086 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,078 · 2020: $8,031 · 2021: $13K · 2022: $23K · 2023: $18K · 2024: $28K · 2025: $9,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $12K · Consulting Fee: $6,320 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,185.00 |
| Food and Beverage | $11,854.24 |
| Consulting Fee | $6,320.20 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $455.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $29,322.62 | 2022-2024 | Verzenio |
| Merck Sharp & Dohme LLC | $23,480.52 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $16,039.60 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astrazeneca Pharmaceuticals LP | $11,497.88 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Eli Lilly Export S.A. Puerto Rico Branch | $7,806.17 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $4,076.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,552.41 | 2019-2025 | Erleada, Rybrevant, Akeega |
| R-Pharm US LLC | $1,516.57 | 2019-2020 | |
| Abbvie INC. | $1,455.39 | 2019-2025 | Venclexta, Lupron Depot |
| Pbg Puerto Rico LLC | $1,414.55 | 2019-2025 | |
| Amgen INC. | $1,348.85 | 2019-2025 | Xgeva, Lumakras, Kyprolis |
| Genentech USA, INC. | $1,005.63 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Puma Biotechnology, INC. | $726.23 | 2019-2025 | Nerlynx |
| Gilead Sciences, INC. | $618.48 | 2022-2025 | Trodelvy |
| Bayer Puerto Rico INC. | $511.14 | 2023-2025 | Nubeqa, Stivarga, Vitrakvi |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $420.92 | 2019-2024 | Erleada |
| Genzyme Corporation | $407.59 | 2019-2025 | |
| Eisai INC. | $286.22 | 2019-2025 | |
| Seagen INC. | $271.95 | 2019-2025 | Tukysa |
| Pfizer INC. | $267.36 | 2019-2023 | |
| Taiho Oncology, INC. | $254.84 | 2019-2025 | |
| Astellas Pharma US INC | $225.16 | 2019-2025 | Xospata |
| Glaxosmithkline, LLC. | $222.03 | 2020-2025 | Zejula, Ojjaara, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $220.18 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $188.68 | 2019-2023 | |
| Clovis Oncology, INC. | $182.79 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $155.02 | 2024-2025 | Libtayo |
| Rigel Pharmaceuticals, INC. | $116.81 | 2021-2025 | Gavreto, Rezlidhia, Tavalisse |
| Tempus Ai, INC | $116.23 | 2025 | Xt Cdx |
| Incyte Corporation | $112.64 | 2019 | |
| Tolmar, INC. | $107.43 | 2023-2025 | Eligard, Rubraca |
| Exelixis INC. | $104.56 | 2019-2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $99.99 | 2022 | |
| Pfizer Pharmaceuticals LLC | $55.23 | 2019 | |
| Pharmaessentia USA Corporation | $52.12 | 2023 | Besremi |
| Jazz Pharmaceuticals INC. | $42.20 | 2021-2025 | |
| Caris Mpi, INC. | $37.34 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $37.28 | 2023-2025 | Orserdu |
| Tolmar Pharmaceuticals, INC. | $33.18 | 2022 | |
| Telix Pharmaceuticals | $24.88 | 2025 | Illuccix |
| Pharmaand Gmbh | $23.65 | 2025 | Rubraca |
| Mirati Therapeutics, INC. | $21.26 | 2023 | Krazati |
| Verity Pharmaceuticals INC. | $21.08 | 2022 | |
| Cti Biopharma Corp. | $20.59 | 2023 | Vonjo |
| Beigene USA, INC. | $18.97 | 2022 | |
| Springworks Therapeutics, INC. | $18.69 | 2025 | Ogsiveo |
| Deciphera Pharmaceuticals INC. | $16.95 | 2022 | |
| Celgene Corporation | $16.67 | 2019 | |
| Shire North American Group INC | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Baez Vallecillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.